CDLX Form 144: Amit Gupta prior sales total 143,670 shares
Rhea-AI Filing Summary
Cardlytics, Inc. (CDLX) disclosure shows a proposed insider sale of 7,799 common shares through Fidelity Brokerage Services on 10/02/2025 with an aggregate market value of $17,710.75. The shares were acquired on 10/01/2025 upon restricted stock vesting and were granted as compensation. The filing lists total common shares outstanding as 53,236,901. The filer also reported three sales by Amit Gupta in the prior three months: 6,725 shares on 07/02/2025 (gross proceeds $11,987.99), 68,260 shares on 08/18/2025 (gross proceeds $76,806.15), and 68,685 shares on 08/19/2025 (gross proceeds $76,803.57), totaling 143,670 shares and $165,597.71 in gross proceeds. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Positive
- Restricted stock vesting clearly disclosed: 7,799 shares acquired 10/01/2025 as compensation
- Proposed sale notice filed as LIVE and names the executing broker Fidelity Brokerage Services
- Filer attests there is no undisclosed material adverse information in the issuer
Negative
- Substantial insider selling in prior three months: 143,670 shares sold by Amit Gupta
- Prior three-month gross proceeds total $165,597.71, indicating meaningful insider liquidity
Insights
Insider sale filed for 7,799 vested shares; prior three-month sales totaled 143,670 shares.
The filing documents a proposed market sale on 10/02/2025 of shares acquired through restricted stock vesting on 10/01/2025, indicating these shares were granted as compensation. The seller also disclosed three prior sales by Amit Gupta totaling 143,670 shares for $165,597.71 gross proceeds during July–August 2025.
This record provides transparent compliance with Rule 144 reporting requirements and names Fidelity Brokerage Services as the executing broker.
FAQ
What does the Form 144 for Cardlytics (CDLX) report?
Who sold shares in the past three months according to the filing?
How many total shares were outstanding per the filing?
What were the gross proceeds from the prior three-month insider sales?
Were the proposed shares acquired via purchase or compensation?
Which broker is named for the proposed sale?